Tejas Savant
Stock Analyst at Morgan Stanley
(2.16)
# 2,782
Out of 4,761 analysts
222
Total ratings
38.35%
Success rate
-3.96%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Overweight | $28 → $26 | $10.90 | +138.53% | 13 | Feb 14, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $245 → $250 | $191.04 | +30.86% | 11 | Feb 11, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $150 → $136 | $94.20 | +44.37% | 7 | Feb 11, 2025 | |
| AVTR Avantor | Maintains: Overweight | $27 → $25 | $17.30 | +44.51% | 16 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $647 → $678 | $532.55 | +27.31% | 14 | Jan 31, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $84 → $82 | $64.49 | +27.15% | 8 | Jan 13, 2025 | |
| STVN Stevanato Group | Assumes: Equal-Weight | $24 → $23 | $20.90 | +10.05% | 1 | Dec 3, 2024 | |
| GRAL GRAIL | Initiates: Equal-Weight | $16 | $40.73 | -60.72% | 1 | Nov 27, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $26 → $28 | $39.18 | -28.53% | 13 | Nov 18, 2024 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $32 → $21 | $14.18 | +48.10% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $132 → $176 | $162.31 | +8.43% | 12 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $11 → $10 | $4.11 | +143.31% | 12 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.54 | +29.87% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $2.05 | +46.34% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $68.09 | -35.38% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $10.82 | +269.69% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $5.12 | +36.72% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $11.10 | +53.15% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $8.27 | +20.92% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $6.22 | +157.23% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.54 | +289.61% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.07 | +145.70% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.21 | -14.33% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $4.72 | +6.04% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.26 | +342.48% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $42.87 | +70.28% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $163.02 | +53.36% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.88 | +466.89% | 5 | May 12, 2022 |
10x Genomics
Feb 14, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $10.90
Upside: +138.53%
IQVIA Holdings
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $191.04
Upside: +30.86%
Illumina
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $150 → $136
Current: $94.20
Upside: +44.37%
Avantor
Feb 10, 2025
Maintains: Overweight
Price Target: $27 → $25
Current: $17.30
Upside: +44.51%
Thermo Fisher Scientific
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $532.55
Upside: +27.31%
Hologic
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $84 → $82
Current: $64.49
Upside: +27.15%
Stevanato Group
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $20.90
Upside: +10.05%
GRAIL
Nov 27, 2024
Initiates: Equal-Weight
Price Target: $16
Current: $40.73
Upside: -60.72%
Veracyte
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $39.18
Upside: -28.53%
Myriad Genetics
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $14.18
Upside: +48.10%
Nov 14, 2024
Maintains: Overweight
Price Target: $132 → $176
Current: $162.31
Upside: +8.43%
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $11 → $10
Current: $4.11
Upside: +143.31%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.54
Upside: +29.87%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $2.05
Upside: +46.34%
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $68.09
Upside: -35.38%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $10.82
Upside: +269.69%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $5.12
Upside: +36.72%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $11.10
Upside: +53.15%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $8.27
Upside: +20.92%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $6.22
Upside: +157.23%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.54
Upside: +289.61%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.07
Upside: +145.70%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.21
Upside: -14.33%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.72
Upside: +6.04%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.26
Upside: +342.48%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $42.87
Upside: +70.28%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $163.02
Upside: +53.36%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.88
Upside: +466.89%